Get better Answers
With Innovative, Adaptive Clinical Trials.
Berry Consultants ("Berry") is a scientific consulting company specializing in innovative adaptive clinical trial design, analysis, implementation, and software solutions for the pharmaceutical and medical device industry.
To seek efficient answers for new medical advancements, you need more. That’s why Berry offers innovative statisticians and software for the freedom to design and implement adaptive clinical trials. Get the answers you need from analysis to approval and beyond.
Innovative Trials, Better Outcomes.
Berry has extensive experience in the design, implementation, and software solutions of adaptive clinical trials across many medical disciplines. Adaptive trials can result in better insights, greater efficiency, better treatment for subject in a trial, and better information for regulators and the medical community. Here’s the Adaptive Trial Process.
Adaptive Clinical Trial Design
Allow the pre-specification of flexible components to the major aspects of a trial, like the treatment arms, the allocation to the different treatment arms, the patient population, and the sample size.
Trial Implementation
Our services include interim and final analyses for primary and key secondary efficacy endpoints, providing expert guidance on best practices for adaptive design implementation, and interacting with Data Safety Monitoring Boards (DSMB) for adaptive and platform trials.
Clinical Trial Software
Software solutions that help Biostatisticians rapidly design, compare, and simulate both fixed and adaptive trial designs through powerful, versatile and fast simulation tools.
Platform Trials
Innovative clinical trials that evaluate multiple treatments simultaneously and intended to continue beyond the evaluation of any one treatment, while maximizing statistical and clinical efficiency.
Latest News and Events
Episode 45, “Path 2 Parkinson’s Prevention with Drs. Simuni and Wendelberger”
In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Tanya Simuni, Arthur C. Nielsen Jr. Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorders Center at Northwestern University, and Dr. Barbara Wendelberger, Senior Statistical Scientist at Berry Consultants.
FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials
Today, the FDA published draft guidance designed to facilitate the use of Bayesian methodologies in clinical trials of drugs and biologics, helping sponsors make better use of available data and conduct more efficient clinical trials.
Episode 44, “Statistical Communication”
In this episode of “In the Interim…,” host Dr. Scott Berry examines the challenge of communicating complex statistical concepts to non-statistical audiences.
Episode 43, “The Rumor of One Trial for Substantial Evidence”
In this episode of "In the Interim…", host Dr. Scott Berry and frequent co-host Dr. Kert Viele, Senior Statistical Scientist at Berry Consultants, analyze the potential shift in FDA regulatory policy from requiring two independent trials to accepting a single trial as sufficient for “substantial evidence” in drug approvals.
Latest Publications
We’re continually refining and reshaping the clinical trials for the betterment of our clients and their patients.
